Which AI agents work with Es Cushing Medical Therapy Block Aberrant Receptors Bmah?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Who published Es Cushing Medical Therapy Block Aberrant Receptors Bmah?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Es Cushing Medical Therapy Block Aberrant Receptors Bmah by dromlakhani

Name: Es Cushing Medical Therapy Block Aberrant Receptors Bmah
Rating: 4.5 (4 reviews)
Author: dromlakhani

Es Cushing Medical Therapy Block Aberrant Receptors Bmah

This skill suggests medical therapy to block aberrant hormone receptors for bilateral macronodular adrenal hyperplasia (BMAH) when surgery is not preferred or feasible. Consider this approach in patients with confirmed BMAH and evidence of aberrant hormone receptor expression (e.g., GIP, LH/hCG, serotonin) driving cortisol excess.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Medical Therapy to Block Aberrant Hormone Receptors for Bilateral Macronodular Adrenal Hyperplasia

STEP 1 — Gather Information

Confirm BMAH diagnosis with bilateral adrenal nodules on CT/MRI and hormonal evidence of autonomous cortisol secretion (elevated UFC, non‑suppressible cortisol). Assess patient preference and surgical feasibility. Perform adrenal vein sampling or hormone challenge tests (meal, GIP, LH/hCG, serotonin) to identify aberrant hormone receptors driving cortisol excess.

STEP 2 — Rule In / Rule Out

Rule in aberrant hormone receptor expression if hormone challenge provokes a cortisol rise >20% or adrenal vein sampling shows receptor‑linked secretion; rule out if no such reactivity is detected.

STEP 3 — Classify or Stratify

Classify the aberrant receptor type (e.g., GIP receptor, LH/hCG receptor, serotonin receptor, adrenal androgen receptor) to guide selection of specific antagonist therapy.

STEP 4 — Decide

Initiate medical therapy targeting the identified aberrant receptor (e.g., ketoconazole or metyrapone for steroidogenesis inhibition, or receptor‑specific antagonists such as cyproheptadine for serotonin, GnRH antagonist for LH/hCG, or investigational GIP antagonist) with the goal of normalizing cortisol levels.

Clinical Guardrails / Mimics / Pitfalls

Do not use receptor‑blocking therapy when surgery is feasible and preferred; avoid in patients with known hypersensitivity to the chosen agent; monitor for adrenal insufficiency and hypocortisolism; do not rely solely on receptor blockade if cortisol remains elevated, as adjunctive steroidogenesis inhibition may be needed; avoid agents that stimulate cortisol secretion (e.g., exogenous ACTH).

Concrete Clinical Example

A 48‑year‑old woman with bilateral adrenal nodules on CT, unsuppressed cortisol, declines surgery due to cardiac risk. Adrenal vein sampling after oral GIP shows a 45% cortisol rise, indicating aberrant GIP receptor. She is started on ketoconazole 400 mg twice daily; after 3 weeks UFC falls to normal range and symptoms improve.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI: 10.1210/jc.2015-1818

---name: es-cushing-medical-therapy-block-aberrant-receptors-bmahdescription: This skill suggests medical therapy to block aberrant hormone receptors for bilateral macronodular adrenal hyperplasia (BMAH) when surgery is not preferred or feasible. Consider this approach in patients with confirmed BMAH and evidence of aberrant hormone receptor expression (e.g., GIP, LH/hCG, serotonin) driving cortisol excess.---# Medical Therapy to Block Aberrant Hormone Receptors for Bilateral Macronodular Adrenal Hyperplasia## STEP 1 — Gather InformationConfirm BMAH diagnosis with bilateral adrenal nodules on CT/MRI and hormonal evidence of autonomous cortisol secretion (elevated UFC, non‑suppressible cortisol). Assess patient preference and surgical feasibility. Perform adrenal vein sampling or hormone challenge tests (meal, GIP, LH/hCG, serotonin) to identify aberrant hormone receptors driving cortisol excess.## STEP 2 — Rule In / Rule OutRule in aberrant hormone receptor expression if hormone challenge provokes a cortisol rise >20% or adrenal vein sampling shows receptor‑linked secretion; rule out if no such reactivity is detected.## STEP 3 — Classify or StratifyClassify the aberrant receptor type (e.g., GIP receptor, LH/hCG receptor, serotonin receptor, adrenal androgen receptor) to guide selection of specific antagonist therapy.## STEP 4 — DecideInitiate medical therapy targeting the identified aberrant receptor (e.g., ketoconazole or metyrapone for steroidogenesis inhibition, or receptor‑specific antagonists such as cyproheptadine for serotonin, GnRH antagonist for LH/hCG, or investigational GIP antagonist) with the goal of normalizing cortisol levels.## Clinical Guardrails / Mimics / PitfallsDo not use receptor‑blocking therapy when surgery is feasible and preferred; avoid in patients with known hypersensitivity to the chosen agent; monitor for adrenal insufficiency and hypocortisolism; do not rely solely on receptor blockade if cortisol remains elevated, as adjunctive steroidogenesis inhibition may be needed; avoid agents that stimulate cortisol secretion (e.g., exogenous ACTH).## Concrete Clinical ExampleA 48‑year‑old woman with bilateral adrenal nodules on CT, unsuppressed cortisol, declines surgery due to cardiac risk. Adrenal vein sampling after oral GIP shows a 45% cortisol rise, indicating aberrant GIP receptor. She is started on ketoconazole 400 mg twice daily; after 3 weeks UFC falls to normal range and symptoms improve.**Source:** Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI: 10.1210/jc.2015-1818

Frequently asked questions